Explore innovative Type 2 diabetes drugs that enhance insulin sensitivity and reduce side effects from older treatments.

Explore the role of depression drugs targeting the neurokinin-1 receptor and their potential impact on major depressive ...

The first COPD patient has been dosed in a Phase 1b COPD trial testing Bambusa Therapeutics’ dual-target therapy BBT002.

Novo Nordisk is expanding its prospects in obesity and other metabolic disorders by securing rights to an early-clinical engineered peptide whose effects comes from activating three receptors — the ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way to measure the effect ...

A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...